S1 Appendix: PROSPERO registration and final review protocol

This supplementary file contains our PROSPERO registration (CRD42018106765) and most recent review protocol.

Please note that our final review protocol revision was completed on January 3, 2020. The PROSPERO website has experienced substantial delays in 2020. At the date of our manuscript’s submission on May 5, 2020, our revision on the PROSPERO website is still listed as “Records that are being assessed.” We include full documentation here for transparency.
You have 1 records

Records that are being assessed

These records have been submitted for publication and are being assessed by the editorial team. You cannot make changes to these records while they are going through the editorial process.

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Status</th>
<th>Last edited</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRD42018106765</td>
<td>Health system interventions to improve clinical and patient-centered outcomes for adults with type 2 diabetes in low- and middle-income countries: A systematic review and meta-analysis</td>
<td>Registered</td>
<td>03/01/2020</td>
</tr>
</tbody>
</table>
Systematic review

Give the working title of the review, for example the one used for obtaining funding. Ideally the title should state succinctly the interventions or exposures being reviewed and the associated health or social problems. Where appropriate, the title should use the PI(E)COS structure to contain information on the Participants, Intervention (or Exposure) and Comparison groups, the Outcomes to be measured and Study designs to be included.

Health system interventions to improve clinical and patient-centered outcomes for adults with type 2 diabetes in low- and middle-income countries: A systematic review and meta-analysis

2. Original language title.
For reviews in languages other than English, this field should be used to enter the title in the language of the review. This will be displayed together with the English language title.

3. * Anticipated or actual start date.
Give the date when the systematic review commenced, or is expected to commence.

25/08/2018

4. * Anticipated completion date.
Give the date by which the review is expected to be completed.

01/03/2020

5. * Stage of review at time of this submission.
Indicate the stage of progress of the review by ticking the relevant Started and Completed boxes. Additional information may be added in the free text box provided.

Please note: Reviews that have progressed beyond the point of completing data extraction at the time of initial registration are not eligible for inclusion in PROSPERO. Should evidence of incorrect status and/or completion date being supplied at the time of submission come to light, the content of the PROSPERO record will be removed leaving only the title and named contact details and a statement that inaccuracies in the stage of the review date had been identified.

This field should be updated when any amendments are made to a published record and on completion and publication of the review. If this field was pre-populated from the initial screening questions then you are not able to edit it until the record is published.

The review has not yet started: No
### Review stage

<table>
<thead>
<tr>
<th>Review stage</th>
<th>Started</th>
<th>Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preliminary searches</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Piloting of the study selection process</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Formal screening of search results against eligibility criteria</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Data extraction</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Risk of bias (quality) assessment</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Data analysis</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Provide any other relevant information about the stage of the review here (e.g. Funded proposal, protocol not yet finalised).

### 6. * Named contact.

The named contact acts as the guarantor for the accuracy of the information presented in the register record.

David Flood

**Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence:**

David

### 7. * Named contact email.

Give the electronic mail address of the named contact.

david@wuqukawoq.org

### 8. Named contact address

Give the full postal address for the named contact.

2 calle 5-43 zona 1, Santiago Sacatepéquez, Guatemala 03006

### 9. Named contact phone number.

Give the telephone number for the named contact, including international dialling code.

502-7840-3112

### 10. * Organisational affiliation of the review.

Full title of the organisational affiliations for this review and website address if available. This field may be completed as 'None' if the review is not affiliated to any organisation.

Wuqu’ Kawoq | Maya Health Alliance

**Organisation web address:**

http://www.wuqukawoq.org

### 11. * Review team members and their organisational affiliations.
PROSPERO
International prospective register of systematic reviews

Give the personal details and the organisational affiliations of each member of the review team. Affiliation refers to groups or organisations to which review team members belong. **NOTE: email and country are now mandatory fields for each person.**

David Flood. Wuqu’ Kawoq | Maya Health Alliance, Santiago Sacatepéquez, Guatemala; National Clinicians Scholars Program and Division of Hospital Medicine, University of Michigan
Jessica Gaulter. Medicine-Pediatrics Residency Program, University of Minnesota
Matthew Dunn. School of Public Health, University of Michigan
Sarah Jane Brown. Health Sciences Libraries, University of Minnesota, Minneapolis
Bradley H. Wagenaar. Department of Global Health, University of Washington
Elizabeth A. Rogers. Division of General Internal Medicine, University of Minnesota
Michele Heisler. Department of Internal Medicine and Institute for Healthcare Policy and Innovation, University of Michigan; Center for Clinical Management Research, Veterans Affairs Ann Arbor Healthcare System
Vineet Chopra. Division of Hospital Medicine, Department of Medicine, University of Michigan
Peter Rohloff. Centro de Investigación en La Salud Indígena, Wuqu’ Kawoq | Maya Health Alliance, Santiago Sacatepéquez, Guatemala; Division of Global Health Equity, Brigham and Women’s Hospital, Boston, MA, USA

12. * Funding sources/sponsors.*

Give details of the individuals, organizations, groups or other legal entities who take responsibility for initiating, managing, sponsoring and/or financing the review. Include any unique identification numbers assigned to the review by the individuals or bodies listed.

The authors received no specific sources of funding for this work.

Grant number(s)

13. * Conflicts of interest.*

List any conditions that could lead to actual or perceived undue influence on judgements concerning the main topic investigated in the review.

None


Give the name and affiliation of any individuals or organisations who are working on the review but who are not listed as review team members. **NOTE: email and country are now mandatory fields for each person.**

Dr Timothy Wilt. Center for Chronic Disease Outcomes Research, Minneapolis Veterans Affairs Health Care System, Minneapolis, MN, USA


State the question(s) to be addressed by the review, clearly and precisely. Review questions may be specific or broad. It may be appropriate to break very broad questions down into a series of related more specific questions. Questions may be framed or refined using PI(E)COS where relevant.

What are the effectiveness and harms of health system interventions to improve glycemic control for adults with type 2 diabetes in in low- and middle-income countries?


State the sources that will be searched. Give the search dates, and any restrictions (e.g. language or publication period). Do NOT enter the full search strategy (it may be provided as a link or attachment.)

We will search the following electronic bibliographic databases: Ovid MEDLINE, Cochrane Library, EMBASE,
African Index Medicus, LILACS, and Global Index Medicus. We also will manually review reference lists of all included studies, related systematic reviews in PROSPERO, and the websites of major international diabetes organizations (International Diabetes Federation, World Diabetes Foundation, Global Alliance for Chronic Diseases, and World Health Organization) for additional potentially eligible studies.

Our search strategy will intersect three concepts: (1) type 2 diabetes, (2) LMICs, and (3) study design. We will not incorporate search terms relating to specific health system interventions as such interventions are summarized and indexed using widely heterogeneous descriptions.

17. URL to search strategy.

Give a link to a published pdf/word document detailing either the search strategy or an example of a search strategy for a specific database if available (including the keywords that will be used in the search strategies), or upload your search strategy. Do NOT provide links to your search results.

https://www.crd.york.ac.uk/PROSPEROFILES/106765_STRATEGY_20191120.pdf

Alternatively, upload your search strategy to CRD in pdf format. Please note that by doing so you are consenting to the file being made publicly accessible.

Do not make this file publicly available until the review is complete

18. * Condition or domain being studied.

Give a short description of the disease, condition or healthcare domain being studied. This could include health and wellbeing outcomes.

Type 2 diabetes conveys a high burden of death and disability globally that disproportionately impacts people in low- and middle-income countries (LMICs). Developing health systems interventions to address the morbidity, mortality, and costs related to diabetes in LMICs is thus a global health priority. However, systematic reviews examining the role of diabetes health systems or quality improvement strategies include few studies outside of high-income countries. This review aims to provide a general assessment of the effectiveness and harms of various health system interventions to improve type 2 diabetes outcomes in LMICs.


Give summary criteria for the participants or populations being studied by the review. The preferred format includes details of both inclusion and exclusion criteria.

Inclusion: Non-pregnant, community-dwelling adults aged 18 years or older with type 2 diabetes in low- or middle-income countries. Studies must include at least 100 total participants.

Exclusion: People with other forms of diabetes or diabetes risk (e.g., prediabetes, gestational diabetes, or type 1 diabetes). We also excluded interventions focused on Ramadan, insulin titration, or glucose self-monitoring as nuances related to these unique contexts limit generalizability.

20. * Intervention(s), exposure(s).
Give full and clear descriptions or definitions of the nature of the interventions or the exposures to be reviewed.

We define a health systems intervention as one “designed to improve professional practice and the delivery of effective health services.” Included studies describe an intervention within the four domains of EPOC health system interventions. We will exclude trials of patient behavior change alone if health-care professional behavior is not primarily influenced. We define “health-care professional” broadly to encompass physicians, nurses, pharmacists, and other allied health workers. Thus, an intervention aiming to improve glycemic control by training health-care professionals on diabetes education will be included; however, an intervention aiming to improve patient glycemic control solely through individualized diabetes education will be excluded.

21. * Comparator(s)/control.
Where relevant, give details of the alternatives against which the main subject/topic of the review will be compared (e.g. another intervention or a non-exposed control group). The preferred format includes details of both inclusion and exclusion criteria.
Usual or enhanced usual care

22. * Types of study to be included.
Give details of the types of study (study designs) eligible for inclusion in the review. If there are no restrictions on the types of study design eligible for inclusion, or certain study types are excluded, this should be stated. The preferred format includes details of both inclusion and exclusion criteria.
Included: We will include randomized trials and cluster randomized trials. Cluster randomized trials must have at least two intervention and control sites to be included.
Excluded: Non-randomized trials, controlled and uncontrolled before-after studies, cohort studies, cross-sectional studies, case-control studies, or case series.

Give summary details of the setting and other relevant characteristics which help define the inclusion or exclusion criteria.
We will include randomized controlled trials (RCTs) of health systems interventions conducted in at least one LMIC as defined by 2019 World Bank lending categories. We pre-specified that included studies were published in English, enrolled 100 or more participants for at least 24 weeks, and reported at least one of the following outcomes: glycemic changes, mortality, health-related quality of life, or resource utilization. We will exclude interventions focused on Ramadan, insulin titration, or glucose self-monitoring as nuances related to these unique contexts limit generalizability. No date restrictions were applied.

24. * Main outcome(s).
Give the pre-specified main (most important) outcomes of the review, including details of how the outcome is defined and measured and when these measurements are made, if these are part of the review inclusion criteria.
Outcomes: Glycemic changes (hemoglobin A1c or fasting blood glucose), mortality, health-related quality of
life (using a standardized instrument), or resource utilization (using cost-effectiveness or cost-utility analysis). Included studies had to report at least one of the above outcomes. If outcomes were not reported or missing, we will contact study authors via email to inquire about these data.

* Measures of effect
Please specify the effect measure(s) for your main outcome(s) e.g. relative risks, odds ratios, risk difference, and/or ‘number needed to treat.

N/A

25. * Additional outcome(s).
List the pre-specified additional outcomes of the review, with a similar level of detail to that required for main outcomes. Where there are no additional outcomes please state ‘None’ or ‘Not applicable’ as appropriate to the review.

None

* Measures of effect
Please specify the effect measure(s) for your additional outcome(s) e.g. relative risks, odds ratios, risk difference, and/or ‘number needed to treat.

N/A

26. * Data extraction (selection and coding).
Describe how studies will be selected for inclusion. State what data will be extracted or obtained. State how this will be done and recorded.

Data management
An information specialist (SJB) will download all titles and abstracts retrieved by electronic searches to EndNote, remove duplicates, and then import to the web-based systematic review tool Covidence.

Selection process
Two review authors (DF and JG) will use Covidence to independently screen studies by title and abstract, and, subsequently, by full-text review. We will note the reason for ineligibility of studies selected for full-text screening but then subsequently excluded. We will resolve any disagreements in the screening process first by discussion between the two reviewers conducting the screening; if disagreements persist, a third review author will be consulted (PR). We will produce a PRISMA flow diagram of the selection process using Covidence. The unit of interest in this review is a single intervention, and we will aggregate multiple reports of the same intervention for extraction and analysis.

Data collection process
PROSPERO
International prospective register of systematic reviews

We will adapt relevant items from the standard EPOC data collection template to generate and pilot a customized electronic extraction spreadsheet. Three review authors (DF, JG, and MD) will each independently review all extracted data.

Describe the method of assessing risk of bias or quality assessment. State which characteristics of the studies will be assessed and any formal risk of bias tools that will be used.
Two reviewers (DF and JG) will independently assess risk of bias in Covidence for each study using the methodology recommended by EPOC. Disagreements will be resolved by discussion between the initial two reviews or, if required, with assistance from a third reviewer (PR).

Provide details of the planned synthesis including a rationale for the methods selected. This must not be generic text but should be specific to your review and describe how the proposed analysis will be applied to your data.
We will generate tables describing included studies by EPOC taxonomy grouping, outcome, and World Bank income level. We will then conduct a narrative synthesis to summarize these results. We will conduct a meta-analysis for the outcome of glycemic changes (i.e., hemoglobin A1c) if we deem studies within similarly categorized groups to have sufficient clinical homogeneity. If a meta-analysis is conducted, we only will incorporate that are not judged as high risk of bias.

29. * Analysis of subgroups or subsets.
State any planned investigation of ‘subgroups’. Be clear and specific about which type of study or participant will be included in each group or covariate investigated. State the planned analytic approach.
As described above, we plan to synthesize and analyze data by EPOC taxonomy grouping, outcome, and World Bank income level.

30. * Type and method of review.
Select the type of review and the review method from the lists below. Select the health area(s) of interest for your review.

Type of review
Cost effectiveness No
Diagnostic No
Epidemiologic No
Individual patient data (IPD) meta-analysis No
Intervention Yes
Meta-analysis Yes
PROSPERO
International prospective register of systematic reviews

Methodology
No

Narrative synthesis
No

Network meta-analysis
No

Pre-clinical
No

Prevention
No

Prognostic
No

Prospective meta-analysis (PMA)
No

Review of reviews
No

Service delivery
No

Synthesis of qualitative studies
No

Systematic review
Yes

Other
No

Health area of the review
Alcohol/substance misuse/abuse
No

Blood and immune system
No

Cancer
No

Cardiovascular
Yes

Care of the elderly
No

Child health
No

Complementary therapies
No

Crime and justice
No

Dental
No

Digestive system
No

Ear, nose and throat
No

Education
No

Endocrine and metabolic disorders
Yes
Eye disorders
No
General interest
Yes
Genetics
No
Health inequalities/health equity
Yes
Infections and infestations
No
International development
No
Mental health and behavioural conditions
No
Musculoskeletal
No
Neurological
No
Nursing
No
Obstetrics and gynaecology
No
Oral health
No
Palliative care
No
Perioperative care
No
Physiotherapy
No
Pregnancy and childbirth
No
Public health (including social determinants of health)
No
Rehabilitation
No
Respiratory disorders
No
Service delivery
No
Skin disorders
No
Social care
No
Surgery
No
Tropical Medicine
No
Urological
No
31. Language.
Select each language individually to add it to the list below, use the bin icon to remove any added in error.
English
There is not an English language summary

Select the country in which the review is being carried out from the drop down list. For multi-national collaborations select all the countries involved.
Guatemala
United States of America

33. Other registration details.
Give the name of any organisation where the systematic review title or protocol is registered (such as with The Campbell Collaboration, or The Joanna Briggs Institute) together with any unique identification number assigned. (N.B. Registration details for Cochrane protocols will be automatically entered). If extracted data will be stored and made available through a repository such as the Systematic Review Data Repository (SRDR), details and a link should be included here. If none, leave blank.

34. Reference and/or URL for published protocol.
Give the citation and link for the published protocol, if there is one
Give the link to the published protocol.
https://www.crd.york.ac.uk/PROSPEROFILES/106765_PROTOCOL_20200103.pdf
Alternatively, upload your published protocol to CRD in pdf format. Please note that by doing so you are consenting to the file being made publicly accessible.
No I do not make this file publicly available until the review is complete
Please note that the information required in the PROSPERO registration form must be completed in full even if access to a protocol is given.

35. Dissemination plans.
Give brief details of plans for communicating essential messages from the review to the appropriate audiences.

Do you intend to publish the review on completion?
Yes

36. Keywords.
Give words or phrases that best describe the review. Separate keywords with a semicolon or new line. Keywords will help users find the review in the Register (the words do not appear in the public record but are included in searches). Be as specific and precise as possible. Avoid acronyms and abbreviations unless these are in wide use.
37. Details of any existing review of the same topic by the same authors.
Give details of earlier versions of the systematic review if an update of an existing review is being registered, including full bibliographic reference if possible.

38. * Current review status.
Review status should be updated when the review is completed and when it is published. For new registrations the review must be Ongoing.
Please provide anticipated publication date
Review_Ongoing

39. Any additional information.
Provide any other information the review team feel is relevant to the registration of the review.

40. Details of final report/publication(s).
This field should be left empty until details of the completed review are available.
Give the link to the published review.
Health system interventions to improve clinical and patient-centered outcomes for adults with type 2 diabetes in low- and middle-income countries: A systematic review and meta-analysis

Review protocol
Version: January 3, 2020

David Flood: Maya Health Alliance, Santiago Sacatepéquez, Guatemala; Division of Hospital Medicine, Department of Medicine, University of Michigan

Matthew Dunn: School of Public Health, University of Michigan

Jessica Gaulter: Medicine-Pediatrics Residency Program, University of Minnesota

Sarah Jane Brown: Health Sciences Libraries, University of Minnesota

Bradley H. Wagenaar: Department of Global Health, University of Washington

Elizabeth A. Rogers: Division of General Internal Medicine, University of Minnesota

Michele Heisler: Department of Internal Medicine and Institute for Healthcare Policy and Innovation, University of Michigan; Center for Clinical Management Research, Veterans Affairs Ann Arbor Healthcare System

Vineet Chopra: Division of Hospital Medicine, Department of Medicine, University of Michigan; Center for Clinical Management Research, Veterans Affairs Ann Arbor Healthcare System

Peter Rohloff: Maya Health Alliance, Santiago Sacatepéquez; Division of Global Health Equity, Brigham and Women’s Hospital

Acknowledgements: Timothy J. Wilt: Center for Chronic Disease Outcomes Research, Minneapolis Veterans Affairs Health Care System, Minneapolis

Corresponding author:
David Flood
Wuqu’ Kawoq | Maya Health Alliance
2 calle 5-43 zona 1
Santiago Sacatepéquez
Guatemala 03006
BACKGROUND

Rationale

Type 2 diabetes mellitus (T2DM) conveys a high burden of death and disability globally that disproportionately impacts people in low- and middle-income countries (LMICs). Of the 450 million people worldwide with T2DM, approximately 80% reside in LMICs. From 1980-2014, the absolute number of people and percent of the population with diabetes increased more quickly in LMICs than in high-income countries (HICs). People with diabetes in LMICs experience premature and morbidity and mortality relative to HICs.

The design and implementation of interventions to effectively address the diabetes burden in LMICs is thus a global health priority. However, systematic reviews examining health systems interventions or quality improvement strategies for diabetes have included few studies in LMICs. Given differences in health system infrastructure, resources, and population risk factors, it should not be assumed that interventions designed and tested in HICs are generalizable.

Among the few diabetes interventions reported from LMICs, studies have focused on prevention, regional evidence, or specific interventions such as task shifting, deployment of community health workers, or lifestyle change. Other reviews of cardiovascular disease interventions in LMICs have not emphasized diabetes. To date, no review has synthesized evidence across different types of health system interventions to improve type 2 diabetes outcomes in LMICs.

Therefore, we will examine the impact of health system interventions aiming to improve clinical and patient-centered outcomes for adults with T2DM in LMICs.

METHODS

This systematic review will be conducted based on guidance from the Cochrane Effective Practice and Organisation of Care (EPOC) group, which conducts reviews on health systems interventions. We registered the review in PROSPERO (CRD42018106765) and followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.

Framework

Our PICO summary and analytic framework is described below and in Figure 1. This framework is based on an example from the literature.

- **Population**: Non-pregnant, community-dwelling adults with type 2 diabetes in low- or middle-income countries
- **Interventions**: Health systems interventions aiming to improve clinical and patient-centered outcomes
- **Comparator**: Usual Care
- **Outcomes**: 
- Clinical outcomes: Mortality and health-related quality of life (using any standardized instrument)
- Intermediate outcomes: Absolute change in glycemic control indicator (hemoglobin A1c of fasting blood glucose)
- Resource utilization: Cost-effectiveness (using cost-effectiveness or cost-utility analysis)

Figure 1: PICO framework.

Search strategy and selection criteria

Our search strategy intersects three concepts: type 2 diabetes, LMICs, and study design.25,26 (See Figure 2: Schematic of search strategy.) With the assistance of a research librarian (SJB), we will perform serial searches of Ovid MEDLINE, Cochrane Library, EMBASE, African Index Medicus, LILACS, and Global Index Medicus. To identify additional potentially eligible studies, we also manually will review the references of included studies, related systematic reviews, and the websites of major international diabetes organizations. All searches will be developed in Ovid MEDLINE and syntax will be translated to other bibliographic databases. To ensure search quality, a second reference librarian will peer-review the search terms.
We will included randomized controlled trials (RCTs) of health systems interventions conducted in at least one LMIC as defined by 2019 World Bank lending categories. Both individual and cluster RCTs will be eligible. We pre-specified that included studies were published in English, enrolled 100 or more participants for at least 24 weeks, and reported at least one of the following outcomes: glycemic changes, mortality, health-related quality of life, or resource utilization. We will exclude interventions focused on Ramadan, insulin titration, or glucose self-monitoring as nuances related to these unique contexts limit generalizability. No date restrictions were applied.

We will defin a health systems intervention as one “designed to improve professional practice and the delivery of effective health services.” Included studies will describe an intervention within the four domains of EPOC health system interventions:

- Delivery arrangements: Changes in how, when and where healthcare is organized and delivered, and who delivers healthcare.
- Financial arrangements: Changes in how funds are collected, insurance schemes, how services are purchased, and the use of targeted financial incentives or disincentives
- Governance arrangements: Rules or processes that affect the way in which powers are exercised, particularly with regard to authority, accountability, openness, participation, and coherence.
• Implementation strategies: Interventions designed to bring about changes in healthcare organizations, the behavior of healthcare professionals, or the use of health services by healthcare recipients.

We will exclude trials of patient behavior change alone if health-care professional behavior is not primarily influenced. We define “health-care professional” broadly to encompass physicians, nurses, pharmacists, and other allied health workers. Thus, an intervention training health-care professionals on diabetes education will be included; however, an intervention aiming to improve outcomes solely through individualized diabetes education will be excluded.

Data analysis

A reference librarian (SJB) will download all records to Endnote, remove duplicates, and import records to Covidence®. Two authors (DF and JG) will independently screen studies by title and abstract and, subsequently, by full-text review. Disagreements will be resolved first by consensus and, if needed, in consultation with a third author (PR). We will aggregate multiple reports of the same intervention for extraction and analysis. We will use the TIDieR checklist and EPOC template to structure extraction. One author (DF) will extract summary data into a customized electronic spreadsheet, and a second author (JG) independently verified the extracted data. In addition relevant outcomes, we will extract study elements including country, setting, duration and follow-up, number of participants enrolled, intervention description, and comparator. We will classify each study by one or more taxonomy category from EPOC. Within each category, we will use consensus between two reviewers (DF and JG) to group interventions into similar subcategories. If outcomes are not reported or missing, we will authors twice over four weeks via email to obtain these data. To assess risk of bias, two reviewers (DF and JG) independently will assess studies using the Cochrane EPOC tool. Disagreements will be resolved by discussion between the two reviewers and, if needed, in consultation with a third reviewer (PR). We will summarize findings using EPOC guidance.

Statistical analysis

We will conduct a meta-analysis if we deem studies within similarly categorized groups to have sufficient clinical homogeneity. We likely would conduct a meta-analysis for the glycemic outcome only and limit studies to those not judged as having high risk of bias. We plan to use random-effects meta-analysis models for mean between-group difference of hemoglobin A1c (HbA1c) change in each intervention category. The meta-analysis may be restricted to trials not classified as high risk of bias. Sample sizes for cluster RCTs would be adjusted to account for the design effect using the intracluster correlation coefficient. We would follow the methodology recommended in the Cochrane handbook to derive within-group mean and standard deviation when complete HbA1c results were not reported. Analyses will be performed in Stata (16.0). Heterogeneity will be quantified by calculating $I^2$ and $T^2$. We might perform exploratory analyses by excluding trials in which the comparator arm was enhanced usual care and/or constructing meta-regression models with baseline HbA1c as a covariate. Publication bias would be assessed by visual inspection of funnel plots. We would use GRADE and EPOC guidance to prepare a summary of findings table for the outcome of glycemic control.
Role of the funding source

There is no funding source for this study. The corresponding author will have full access to all the data in the study and will have final responsibility for the decision to submit for publication.
References


26. Effective Practice and Organisation of Care (EPOC). How to develop a search strategy for an intervention review. 2017; Available from: http://epoc.cochrane.org/epoc-specific-resources-review-authors


30. Effective Practice and Organisation of Care (EPOC). Data collection form 2017; Available from: http://epoc.cochrane.org/epoc-specific-resources-review-authors.


32. Effective Practice and Organisation of Care (EPOC). Suggested risk of bias criteria for EPOC reviews. 2017; Available from: http://epoc.cochrane.org/resources/epoc-resources-review-authors.

33. Effective Practice and Organisation of Care (EPOC). Synthesising results when it does not make sense to do a meta-analysis. 2017; Available from: http://epoc.cochrane.org/resources/epoc-resources-review-authors.


36. Effective Practice and Organisation of Care (EPOC). EPOC worksheets for preparing a Summary of Findings (SoF) table using GRADE. 2017; Available from: http://epoc.cochrane.org/resources/epoc-resources-review-authors.